Patents by Inventor Axel F. Brisken

Axel F. Brisken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7050849
    Abstract: Systems for pacing the heart include a vibrational transducer which directs energy at the heart, usually at at least a ventricle, to pace the heart and to promote synchronized contraction of the ventricles. Optionally, additional vibrational and/or electrical stimulation may be provided. The vibrational transducers are usually implantable at a location proximate the heart.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: May 23, 2006
    Assignee: EBR Systems, Inc.
    Inventors: Debra S. Echt, Axel F. Brisken, Richard E. Riley, Mark W. Cowan
  • Patent number: 7006864
    Abstract: Methods and apparatus for cardiac pacing, cardioversion, and defibrillation rely on delivering ultrasonic and other vibrational energy to the heart, usually after the onset of an arrhythmia. A vibrational transducer assembly is implanted or applied externally so that vibrational energy can be directed toward at least a portion of the heart from an anterior or posterior aspect, typically being implanted over the ribs, over the sternum, between the ribs, beneath the ribs, or on the back.
    Type: Grant
    Filed: June 15, 2004
    Date of Patent: February 28, 2006
    Assignee: EBR Systems, Inc.
    Inventors: Debra S. Echt, Axel F. Brisken, Richard E. Riley
  • Publication number: 20040260214
    Abstract: Methods and apparatus for cardiac pacing, cardioversion, and defibrillation rely on delivering ultrasonic and other vibrational energy to the heart, usually after the onset of an arrhythmia. A vibrational transducer assembly is implanted or applied externally so that vibrational energy can be directed toward at least a portion of the heart from an anterior or posterior aspect, typically being implanted over the ribs, over the sternum, between the ribs, beneath the ribs, or on the back.
    Type: Application
    Filed: June 15, 2004
    Publication date: December 23, 2004
    Applicant: EBR Systems, Inc.
    Inventors: Debra S. Echt, Axel F. Brisken, Richard E. Riley
  • Publication number: 20040247576
    Abstract: Methods, systems and devices are provided which promote the uptake of one or more agents into cellular material, wherein incorporation of such agent(s) improve the intended performance of the material upon implantation. This is particularly applicable to vascular replacements wherein uptake of agents, such as nucleic acids, induces long-term stable adaptation of the vascular replacement involving resistance to neointimal hyperplasia and atherosclerosis. The promotion of such uptake is achieved with the use of vibrational energy, particularly ultrasound. The cellular material is immersed into an acoustically transmissive solution comprising the agent. The immersed material is then exposed to vibrational energy under conditions and for a time which promotes incorporation of the agent into the cells. Portable, convenient and easy to use systems and devices are also provided for use in conjunction with these methods.
    Type: Application
    Filed: June 3, 2003
    Publication date: December 9, 2004
    Applicant: PHARMASONICS, INC.
    Inventor: Axel F. Brisken
  • Patent number: 6794369
    Abstract: Nucleic acid transfection of vascular smooth muscle cells is enhanced by the application of vibrational energy to the cells. By applying vibrational energy at frequency in the range from 1 kHz to 10 MHz and at an intensity in the range from 0.01 W/cm2 to 100 W/cm2, significant enhancement of the uptake of nucleic acids into vascular smooth muscle cells can be achieved.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: September 21, 2004
    Assignee: Pharmasonics
    Inventors: Christopher M. H. Newman, Axel F. Brisken
  • Publication number: 20040158317
    Abstract: Methods and apparatus for inhibiting hyperplasia following stent placement are provided. The stents will be coated with pharmaceutical agent(s) and the methods provide for directing vibrational energy at the implanted stents or the blood vessel walls or region of implantation. The vibrational energy can have one or more of several beneficial effects. The vibrational energy may directly inhibit hyperplasia, may effect or modulate release of agent from the stent, or may enhance permeability of the blood vessel wall.
    Type: Application
    Filed: January 26, 2004
    Publication date: August 12, 2004
    Applicant: Pharmasonics, Inc.
    Inventors: Axel F. Brisken, Robert Zuk, John McKenzie
  • Patent number: 6755853
    Abstract: A method for inhibiting hyperplasia at an anastomotic junction of a vascular fistula or vascular graft comprises exposing the anastomotic junction to vibrational energy at a mechanical index and for a time sufficient to inhibit hyperplasia. Kits are described comprising the catheter or a probe suitable for performing the methods together with instructions for use setting forth the methods. The methods and kits are particularly suitable for treating anastomotic junctions formed to provide vascular access for hemodialysis, hemofiltration, and the like. The methods and kits are also suitable for treating other vascular grafts, such as those formed during cardiac bypass graft surgery, vascular repair, and the like.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: June 29, 2004
    Assignee: Pharmasonics, Inc.
    Inventors: John R. McKenzie, Robert F. Zuk, Axel F. Brisken, Paul D. Corl
  • Patent number: 6695785
    Abstract: A catheter including an elongated body member, an ultrasound transducer located on the elongated body member, and dampening means for forming an ultrasound dampening region adjacent to a portion of the ultrasound transducer, is disclosed. The ultrasound transducer is configured to transmit or receive an ultrasound signal. The ultrasound dampening region is configured to improve uniformity of said ultrasound signal in three-dimensional space. Preferably, the dampening means includes air or a material containing air.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: February 24, 2004
    Assignee: Cardiac Pathways Corporation
    Inventors: Axel F. Brisken, N. Parker Willis
  • Publication number: 20040001809
    Abstract: The immune response achieved by the administration of nucleic acid vaccines is enhanced by the application of vibrational energy to the inoculated tissue region. The vibrational energy is selected to enhance transfection of the tissue without substantial tissue damage, relying on a mechanical effect of the vibrational energy. Additionally, vibrational energy intended to mechanically injure the tissue via a thermal effect may also be applied.
    Type: Application
    Filed: June 26, 2002
    Publication date: January 1, 2004
    Applicant: PHARMASONICS, INC.
    Inventors: Axel F. Brisken, Robert Zuk
  • Publication number: 20030229331
    Abstract: A wide beam ultrasound delivery system providing a uniform exposure field is used to enhance the uptake of injected substances and/or to enhance the transfection of DNA in the tissues of human subject, or reduce the amount of vascular intimal hyperplasia in human subjects following vascular injury.
    Type: Application
    Filed: January 10, 2003
    Publication date: December 11, 2003
    Applicant: PHARMASONICS, INC.
    Inventors: Axel F. Brisken, Robert Zuk, John McKenzie, Mark W. Cowan
  • Patent number: 6575956
    Abstract: A wide beam ultrasound delivery system providing a uniform exposure field is used to enhance the uptake of injected substances and/or to enhance the transfection of DNA in the tissues of human subject, or reduce the amount of vascular intimal hyperplasia in human subjects following vascular injury.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: June 10, 2003
    Assignee: Pharmasonics, Inc.
    Inventors: Axel F. Brisken, Robert Zuk, John R. McKenzie, Mark W. Cowan
  • Publication number: 20030069525
    Abstract: Atherosclerotic plaque and blood vessels may be stabilized by directing vibrational energy, typically ultrasonic energy, into the adjacent blood vessel wall. Application of the vibrational energy, optionally in combination with growth factors, growth factor genes, or other substances which enhance growth stability of a fibrotic cap over the plaque, will reduce the risk of rupture of unstable plaque and inhibit the conversion of stable plaque into unstable plaque.
    Type: Application
    Filed: October 24, 2001
    Publication date: April 10, 2003
    Applicant: PHARMASONICS, INC.
    Inventors: Axel F. Brisken, Paulina Moore, Robert F. Zuk
  • Publication number: 20030060737
    Abstract: Post-interventional neointimal hyperplasia in arteries is treated by the application of ultrasonic energy. Usually, an intravascular catheter having an interface surface is positioned at a target site in the artery which has previously been treated. The interface surface is vibrationally excited to apply energy to the arterial wall in a manner which inhibits smooth muscle cell proliferation in the neointimal layer.
    Type: Application
    Filed: September 4, 2002
    Publication date: March 27, 2003
    Applicant: PHARMASONICS, INC.
    Inventor: Axel F. Brisken
  • Publication number: 20030040501
    Abstract: Nucleic acid transfection of vascular smooth muscle cells is enhanced by the application of vibrational energy to the cells. By applying vibrational energy at frequency in the range from 1 kHz to 10 MHz and at an intensity in the range from 0.01 W/cm2 to 100 W/cm2, significant enhancement of the uptake of nucleic acids into vascular smooth muscle cells can be achieved.
    Type: Application
    Filed: August 9, 2002
    Publication date: February 27, 2003
    Applicant: Pharmasonics, Inc.
    Inventors: Christopher M.H. Newman, Axel F. Brisken
  • Patent number: 6524271
    Abstract: A method of treating a target region in a body lumen, said method comprising: directing a uniform dose of ultrasonic energy from an interior of the lumen radially outward over a treatment length of the lumen, wherein the dosage of ultrasonic energy received at any one point along the length varies by no more than plus or minus 6 decibels from that received at any other point along the length.
    Type: Grant
    Filed: July 2, 2001
    Date of Patent: February 25, 2003
    Assignee: Pharmasonics, Inc.
    Inventors: Axel F. Brisken, John R. McKenzie, Robert F. Zuk, Menahem Nassi, Mark W. Cowan, Paul D. Corl
  • Publication number: 20030009153
    Abstract: A method of enhancing cellular absorption of a substance delivered into a target region of a patient's body, comprising: (a) delivering the substance to the target region; and (b) directing vibrational energy to the target region, wherein the vibrational energy is of a type and in an amount sufficient to enhance absorption into cells of the target region.
    Type: Application
    Filed: August 26, 2002
    Publication date: January 9, 2003
    Applicant: Pharmasonics, Inc.
    Inventors: Axel F. Brisken, Robert Zuk
  • Patent number: 6503243
    Abstract: Post-interventional neointimal hyperplasia in arteries is treated by the application of ultrasonic energy. Usually, an intravascular catheter having an interface surface is positioned at a target site in the artery which has previously been treated. The interface surface is vibrationally excited to apply energy to the arterial wall in a manner which inhibits smooth muscle cell proliferation in the neointimal layer.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: January 7, 2003
    Assignee: Pharmasonics, Inc.
    Inventor: Axel F. Brisken
  • Patent number: 6494874
    Abstract: Post-interventional neointimal hyperplasia in arteries is treated by the application of ultrasonic energy. Usually, an intravascular catheter having an interface surface is positioned at a target site in the artery which has previously been treated. The interface surface is vibrationally excited to apply energy to the arterial wall in a manner which inhibits smooth muscle cell proliferation in the neointimal layer.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: December 17, 2002
    Assignee: Pharmasonics, Inc.
    Inventor: Axel F. Brisken
  • Publication number: 20020177889
    Abstract: A catheter comprises a catheter body having an oscillating driver, an interface surface mechanically coupled to the driver, and an inflatable balloon disposed near the interface surface. The balloon may be an angioplasty balloon, in which case the interface surface will deliver ultrasonic or other vibratory energy into a blood vessel as part of an angioplasty or related procedure. Alternatively, the catheter may comprise a pair of axially spaced-apart isolation balloons, in which case the interface surface can deliver ultrasonic or other vibratory energy into a treatment region defined between said balloons. The energy can thus act to mix or enhance penetration of a treatment held between said balloons in performing a vascular treatment procedure.
    Type: Application
    Filed: June 24, 2002
    Publication date: November 28, 2002
    Applicant: PHARMASONICS, INC.
    Inventors: Axel F. Brisken, Vartan E. Ghazarossian
  • Publication number: 20020099292
    Abstract: A catheter including an elongated body member, an ultrasound transducer located on the elongated body member, and dampening means for forming an ultrasound dampening region adjacent to a portion of the ultrasound transducer, is disclosed. The ultrasound transducer is configured to transmit or receive an ultrasound signal. The ultrasound dampening region is configured to improve uniformity of said ultrasound signal in three-dimensional space. Preferably, the dampening means includes air or a material containing air.
    Type: Application
    Filed: August 21, 2001
    Publication date: July 25, 2002
    Applicant: Cardiac Pathways Corporation
    Inventors: Axel F. Brisken, N. Parker Willis